Latest Articles

Publication Date
Engineered Exosomes Restore miR-508-5p Expression in Uterine Corpus Endometrial Carcinoma and Reduce Tumor Progression and Metastasis by Targeting DLL3 - Frontiers

Engineered Exosomes Restore miR-508-5p Expression in Uterine Corpus Endometrial Carcinoma and Reduce Tumor Progression and Metastasis by Targeting DLL3 Frontiers

Published: Feb. 3, 2025, 2:27 p.m.
(PDF) Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment - ResearchGate

(PDF) Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment ResearchGate

Published: Jan. 25, 2025, 1:07 p.m.
Pfizer’s Depo-Provera contraceptive under fire: Study links it to brain tumor risk - MSN

Pfizer’s Depo-Provera contraceptive under fire: Study links it to brain tumor risk MSN

Published: Dec. 31, 2024, 1:41 p.m.
Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment - Frontiers

Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment Frontiers

Published: Dec. 24, 2024, 7:10 p.m.
Deep learning for endometrial cancer subtyping and predicting tumor mutational burden from histopathological slides - Nature.com

Deep learning for endometrial cancer subtyping and predicting tumor mutational burden from histopathological slides Nature.com

Published: Dec. 21, 2024, 9:20 a.m.
HLA-DMB Correlates With Antitumor Immunity and an Improved Prognosis in Endometrial Carcinoma Tumors - Frontiers

HLA-DMB Correlates With Antitumor Immunity and an Improved Prognosis in Endometrial Carcinoma Tumors Frontiers

Published: Dec. 20, 2024, 4:13 p.m.
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without RT for Newly Diagnosed, High-Risk Endometrial Cancer: Results in DMMR Tumors - Medpage Today

Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without RT for Newly Diagnosed, High-Risk Endometrial Cancer: Results in DMMR Tumors Medpage Today

Published: Dec. 18, 2024, 8:16 p.m.
The prognostic value of tumor microenvironment in endometrioid type endometrial cancer: Effect of CD44 on oncologic outcome - ResearchGate

The prognostic value of tumor microenvironment in endometrioid type endometrial cancer: Effect of CD44 on oncologic outcome ResearchGate

Published: Dec. 3, 2024, 6:33 a.m.
Sacituzumab Tirumotecan Shows Antitumor Activity in Previously Treated Endometrial, Ovarian Cancers - OncLive

Sacituzumab Tirumotecan Shows Antitumor Activity in Previously Treated Endometrial, Ovarian Cancers OncLive

Published: Nov. 14, 2024, 8:14 p.m.
IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors - StreetInsider.com

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors StreetInsider.com

Published: Oct. 29, 2024, 10:11 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!